Prevention of atrial fibrillation
73 results
1 - 73
Interventions for preventing post‐operative atrial fibrillation in patients undergoing heart surgery- Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack
- Oral anticoagulants for preventing stroke in patients with non‐valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks
- Antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks
- Antiplatelet therapy for preventing stroke in patients with non‐valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks
- Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
- Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non‐valvular atrial fibrillation
- Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack: Cochrane systematic review
- Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks: Cochrane systematic review
- Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease
- Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter: Cochrane systematic review
- Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation
- Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation
- Systematic screening for the detection of atrial fibrillation
- Clinical service organisation for adults with atrial fibrillation
- Anticoagulants for preventing recurrence following presumed non‐cardioembolic ischaemic stroke or transient ischaemic attack
- Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis
- Perioperative beta‐blockers for preventing surgery‐related mortality and morbidity in adults undergoing cardiac surgery
- Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
- Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias
- Antithrombotic treatment after stroke due to intracerebral haemorrhage
- Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin
- Perioperative beta‐blockers for preventing surgery‐related mortality and morbidity in adults undergoing non‐cardiac surgery
- Anticoagulants versus antiplatelet agents for acute ischaemic stroke
- Preoperative statin therapy for adults undergoing cardiac surgery
- Dual chamber versus single chamber ventricular pacemakers for sick sinus syndrome and atrioventricular block
- Antiplatelet and anticoagulation for patients with prosthetic heart valves
- Optimal loading dose of warfarin for the initiation of oral anticoagulation
- Prophylactic corticosteroids for cardiopulmonary bypass in adult cardiac surgery
- Non‐vitamin K antagonist oral anticoagulants (NOACs) after transcatheter aortic valve replacement (TAVR): a network meta‐analysis
- Prophylactic use of inotropic agents for the prevention of low cardiac output syndrome and mortality in adults undergoing cardiac surgery
- Anticoagulants for people hospitalised with COVID‐19
- Antiplatelet versus anticoagulation treatment for people with heart failure in sinus rhythm
- Febuxostat for treating chronic gout
- Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults
- Colchicine for the primary prevention of cardiovascular events
- Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
- Non‐vitamin‐K‐antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta‐analysis
- Home‐based versus centre‐based cardiac rehabilitation
- Natriuretic peptide‐guided treatment for the prevention of cardiovascular events in patients without heart failure